Laboratoires Théa in the news

Laboratoires Théa sponsors ASM Clermont Auvergne, with its logo on all three team jerseys, highlighting its commitment to the club and shared values.

The Chibret family has a multi-generational history in ophthalmology, culminating in the establishment and European expansion of Laboratoires Théa.

Laboratoires Théa, an ophthalmology pharmaceutical company, is expanding its facilities and building a new factory with Unither in France.

Laboratoires Théa is implementing new employee benefits for caregivers, new parents, and employees nearing retirement, including flexible work, paid leave, and retirement contribution support.

Laboratoires Théa issued a safety alert about inappropriate uses of its Blephademodex wipes, including off-label use and confusion with Blephaclean, which could lead to ineffectiveness or infections.

Thea Pharma launched ZOLYMBUS, a preservative-free ophthalmic gel containing bimatoprost 0.01% for glaucoma and ocular hypertension management in the U.S.

Laboratoires Théa is expanding its ophthalmic portfolio by partnering with Elsalys to develop a new antibody treatment for Age-related Macular Degeneration.

Sophie Momège, founder of Laboratoires Kôl, strengthens ties between the University Clermont Auvergne and ophthalmic pharmaceutical companies.

Larmecran Jour & Nuit is a preservative-free ophthalmic gel that hydrates and protects eyes from dryness linked to prolonged screen use.

Multilarm is a preservative-free eye drop solution with hyaluronic acid for dry and tired eyes, suitable for all ages and contact lens users.

Laboratoires Théa introduced Larmécran® Jour & Nuit, a gel eye drop to treat moderate to severe dry eye from prolonged screen exposure.

Iolyx Therapeutics partnered with Laboratoires Théa to develop and commercialize ILYX-002 for autoimmune dry eye disease, securing $280M in deal value and $15M Series B funding to advance clinical trials and expand its ocular inflammation pipeline.

Iolyx and Laboratoires Théa partnered to develop and commercialize ILYX-002 for ocular surface diseases, with Théa leading phase 3 trials and commercialization outside Asia.

Iolyx Therapeutics partnered with Laboratoires Théa to develop and commercialize ILYX-002 for autoimmune dry eye disease, securing up to $280M in milestones and $15M Series B funding to advance clinical trials and expand its ocular inflammation pipeline.

Laboratoires Théa secured rights to Iolyx's promising phase 3-ready dry eye disease drug ILYX-002 in a deal worth up to $280 million, aiming to advance its development and commercialization globally.

Iolyx Therapeutics partnered with Laboratoires Théa to develop and commercialize ILYX-002 for autoimmune dry eye disease, securing up to $280M in milestones and $15M Series B funding.

Iolyx Therapeutics and Laboratoires Théa partner for ILYX-002 development and commercialization, a deal worth up to $280 million, with Iolyx also raising $15 million for pipeline expansion.

Laboratoires Théa has partnered with Iolyx Therapeutics in a $280 million deal to develop and commercialize a late-stage treatment for autoimmune-associated dry eye disease.

Laboratoires Théa acquired rights to Iolyx's promising phase 3-ready dry eye disease drug ILYX-002 in a deal worth up to $280 million, aiming to advance its development and commercialization globally.

Laboratoires Théa entered a $280 million agreement with Iolyx Therapeutics to develop and commercialize a new treatment for autoimmune-associated dry eye disease.